Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: Case report and review of the literature

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 179-181

  Frech, Tracy M ^a   Hudson, Marie ^b,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Gastrointestinal disease; Immunosuppression; Scleroderma; Systemic sclerosis

Indexed keywords

INTERLEUKIN 6; PROBIOTIC AGENT; RIFAXIMIN; TOCILIZUMAB; IL6 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MIDDLE AGED; PATHOGENESIS; PRIORITY JOURNAL; SKIN DISEASE; SYSTEMIC SCLEROSIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; DISEASE COURSE; GASTROINTESTINAL DISEASES; IMMUNOLOGY; RISK FACTOR; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MIDDLE AGED; RISK FACTORS; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84946222972     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. GYGER G, BARON M: Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 2012; 14:22-29.
2. STEEN VD, MEDSGER TA, Jr.: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
3. HANSI N, THOUA N, CARULLI M et al.: Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 86): S-214-221.
4. KHANNA D, NAGARAJA V, GLADUE H, CHEY W, PIMENTEL M, FRECH T: Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol 2013; 25: 700-6.
5. ERNST M, THIEM S, NGUYEN PM, EISSMANN M, PUTOCZKI TL: Epithelial gp130/Stat3 functions: an intestinal signaling node in health and disease. Semin Immunol 2014; 26: 29-37.
6. ROSSI JF, LU ZY, JOURDAN M, KLEIN B: Interleukin-6 as a therapeutic target. Clin Cancer Res 2015; 21: 1248-57.
7. GOUT T, OSTOR AJ, NISAR MK: Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 2011; 30: 1471-4.
8. CURTIS JR, PEREZ-GUTTHANN S, SUISSA S et al.: Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum 2015; 44: 381-8.
9. KUHN KA, MANIERI NA, LIU TC, STAPPENBECK TS: IL-6 stimulates intestinal epithelial proliferation and repair after injury. PloS one 2014; 9: e114195.
10. KHANNA DDC, van LAAR JM: Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial. ACR 2014; Abstract 874.
11. WOODRICK RS, RUDERMAN EM: Interleukin 6 inhibition-RA and beyond. Bull NYU Hosp Jt Dis 2011; 69: 225-9.
12. OELSCHLAEGER TA: Mechanisms of probiotic actions-A review. Int J Med Microbiol 2010; 300: 57-62.